has entered into an agreement with Maryland-based Omnia Biologics to
manufacture material for its current first-in-man clinical trial for its
TT-034 hepatitis C treatment.
This ensures the company has enough clinical material to complete the current trial.
company is also moving to establish its own scalable manufacturing
process in collaboration with third parties to supply large markets it
Labels: Clinical Trials, TT-034. Benitec